Clinician-Selected FSH Starting Dose and Mature Oocyte Yield in Predicted Poor Responders (OPTIMAL-DOSE)
Association of Clinician-Selected FSH Starting Dose With Mature Oocyte Yield in Women With Predicted Poor Ovarian Response: The OPTIMAL-DOSE Prospective Cohort Study
This is a single-centre, prospective, non-interventional (observational) cohort study examining the association between the clinician-selected starting dose of follicle-stimulating hormone (FSH) and the yield of mature metaphase II (MII) oocytes in women with predicted poor ovarian response (Patient-Oriented Strategies Encompassing IndividualizeD Oocyte Number [POSEIDON] group 3 or 4) undergoing in vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI) with a gonadotropin-releasing hormone (GnRH) antagonist protocol. The FSH dose is chosen by the treating physician as part of routine care; the study does not allocate, randomize, or change treatment. The primary outcome is the number of MII oocytes per initiated index cycle. Because dosing is not randomized, analyses are adjusted for measured confounders and address confounding by indication.
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Detaljeret beskrivelse
Randomized evidence in predicted poor responders (a randomized trial in predicted poor responders and the 2024 Cochrane review of individualised gonadotropin dosing) does not show improved live birth from higher follicle-stimulating hormone (FSH) dosing, so this cohort is not designed to establish comparative efficacy; its contribution is a description of real-world dose-response patterns and local gonadotropin use and cost. Consecutive eligible women are enrolled after informed consent for data use, each contributing one index cycle. The exposure is the clinician-selected starting FSH dose, analysed as a continuous variable (per 75 international units [IU]), with categories of 150 IU or less versus more than 150 IU reported descriptively and in sensitivity analyses. The primary analysis is an adjusted negative-binomial regression of the metaphase II (MII) oocyte count on exposure, with adjusted means obtained by marginal standardization and an overlap-weighted propensity analysis as sensitivity. Reporting follows the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) and REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) statements.
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Kontakter og lokationer
Studiekontakt
Studiekontakt
- Navn: Goksu Goc, MD
- Telefonnummer: +383 49 878 550
- E-mail: goksu.goc@gmail.com
Studiesteder
-
-
-
Pristina, Kosovo, 10000
- American Hospital Kosova
-
Kontakt:
- Goksu Goc, MD
- Telefonnummer: +383 49 878 550
- E-mail: goksu.goc@gmail.com
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Prøveudtagningsmetode
Studiebefolkning
Consecutive women aged 18 to 42 years with predicted poor ovarian response (Patient-Oriented Strategies Encompassing IndividualizeD Oocyte Number (POSEIDON) group 3 or 4: anti-Mullerian hormone below 1.2 ng/mL and/or antral follicle count below 5) undergoing a gonadotropin-releasing hormone (GnRH) antagonist in vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI) cycle as part of routine clinical care at American Hospital Kosova, each contributing one index cycle.
Beskrivelse
Inclusion Criteria:
- Woman aged 18 to 42 years.
- Predicted poor ovarian response, Patient-Oriented Strategies Encompassing IndividualizeD Oocyte Number (POSEIDON) group 3 (under 35 years) or group 4 (35 years or older): anti-Mullerian hormone (AMH) below 1.2 ng/mL and/or antral follicle count (AFC) below 5 (both ovaries combined).
- Planned gonadotropin-releasing hormone (GnRH) antagonist in vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI) cycle as part of routine clinical care.
- First eligible (index) cycle during the study period; both ovaries present.
- Written informed consent for data collection and processing.
Exclusion Criteria:
- Predicted normal or high ovarian reserve (AMH 1.2 ng/mL or higher and AFC 5 or higher).
- Non-antagonist protocol (for example, long GnRH-agonist).
- Oocyte-donation or fertility-preservation (egg-freezing) cycle.
- A prior cycle of the same woman already enrolled in the study.
- Inability to provide informed consent.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Observationsmodeller: COHORT
- Tidsperspektiver: PROSPECTIVE
Antal grupper/kohorter
Kohorter og interventioner
Gruppe / kohorteGruppe / kohorte |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Lower starting dose (150 international units [IU] or less)
Women whose treating physician chose a starting daily follicle-stimulating hormone (FSH) dose of 150 international units (IU) or less as part of routine clinical care (observed, not assigned by the study). |
FSH administered per routine clinical practice; the starting dose is selected by the treating physician (observed exposure, not assigned by the study). Starting dose is analysed continuously (per 75 IU), with categories of 150 IU or less versus more than 150 IU reported descriptively. |
|
Higher starting dose (more than 150 IU)
Women whose treating physician chose a starting daily FSH dose of more than 150 IU (typically 225 IU) as part of routine clinical care (observed, not assigned by the study). |
FSH administered per routine clinical practice; the starting dose is selected by the treating physician (observed exposure, not assigned by the study). Starting dose is analysed continuously (per 75 IU), with categories of 150 IU or less versus more than 150 IU reported descriptively. |
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Number of mature metaphase II (MII) oocytes retrieved
Tidsramme: On the day of oocyte retrieval (up to 21 days after the start of ovarian stimulation)
|
Number of metaphase II (MII) oocytes retrieved per initiated index ovarian stimulation cycle, assessed by the embryologist at a standardized time after oocyte retrieval. Compared across the clinician-selected starting-dose exposure using adjusted analysis (associations, not causal effects). Cycles cancelled before oocyte retrieval contribute zero MII oocytes in the initiated-cycle analysis. Oocytes matured in vitro are excluded from the primary count. |
On the day of oocyte retrieval (up to 21 days after the start of ovarian stimulation)
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Total follicle-stimulating hormone (FSH) activity administered
Tidsramme: From the first to the last day of ovarian stimulation (up to 21 days)
|
Total follicle-stimulating hormone (FSH) activity administered during the index stimulation cycle, in international units (IU), by observed starting-dose exposure. FSH activity is recorded separately from luteinizing hormone (LH) and human chorionic gonadotropin (hCG) activity. |
From the first to the last day of ovarian stimulation (up to 21 days)
|
|
Gonadotropin medication cost
Tidsramme: From the first to the last day of ovarian stimulation (up to 21 days)
|
Cost of the gonadotropin medication used during the stimulation cycle, in euros (EUR), calculated using a pre-specified standardized unit-price table, by observed starting-dose exposure. |
From the first to the last day of ovarian stimulation (up to 21 days)
|
|
Total number of oocytes retrieved
Tidsramme: On the day of oocyte retrieval (up to 21 days after the start of ovarian stimulation)
|
Total number of oocytes retrieved at oocyte pick-up per initiated index cycle, by observed starting-dose exposure. |
On the day of oocyte retrieval (up to 21 days after the start of ovarian stimulation)
|
|
Oocyte maturity rate
Tidsramme: On the day of oocyte retrieval (up to 21 days after the start of ovarian stimulation)
|
Ratio of the number of metaphase II (MII) oocytes to the total number of oocytes retrieved in the index cycle, by observed starting-dose exposure. |
On the day of oocyte retrieval (up to 21 days after the start of ovarian stimulation)
|
|
Cycle cancellation before oocyte retrieval
Tidsramme: From the first day of ovarian stimulation to the planned day of oocyte retrieval (up to 21 days)
|
Whether the initiated index cycle was cancelled before oocyte retrieval, by observed starting-dose exposure. |
From the first day of ovarian stimulation to the planned day of oocyte retrieval (up to 21 days)
|
|
Duration of ovarian stimulation
Tidsramme: From the first to the last day of ovarian stimulation (up to 21 days)
|
Number of days of ovarian stimulation during the index cycle, by observed starting-dose exposure. |
From the first to the last day of ovarian stimulation (up to 21 days)
|
|
Number of normally fertilised oocytes with two pronuclei (2PN)
Tidsramme: At the fertilisation check, 1 day after oocyte retrieval (up to 22 days after the start of ovarian stimulation)
|
Number of oocytes showing two pronuclei (2PN) at the fertilisation check in the index cycle, by observed starting-dose exposure. |
At the fertilisation check, 1 day after oocyte retrieval (up to 22 days after the start of ovarian stimulation)
|
|
Number of usable embryos
Tidsramme: Up to 6 days after oocyte retrieval (up to 27 days after the start of ovarian stimulation)
|
Number of embryos from the index cycle that are transferred, cryopreserved or biopsied, meeting the minimum grade of the pre-specified laboratory standard, by observed starting-dose exposure. Each embryo is counted once. |
Up to 6 days after oocyte retrieval (up to 27 days after the start of ovarian stimulation)
|
|
Number of blastocysts
Tidsramme: Up to 6 days after oocyte retrieval (up to 27 days after the start of ovarian stimulation)
|
Number of embryos from the index cycle reaching the blastocyst stage, by observed starting-dose exposure. |
Up to 6 days after oocyte retrieval (up to 27 days after the start of ovarian stimulation)
|
Andre resultatmål
Andre resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Live birth (exploratory)
Tidsramme: Up to 12 months after the start of ovarian stimulation
|
Delivery of at least one live-born infant, recorded per initiated index cycle and per transfer. Exploratory only; the study is not powered for this outcome and it is highly susceptible to confounding by indication. Reported descriptively. |
Up to 12 months after the start of ovarian stimulation
|
|
Clinical pregnancy (exploratory)
Tidsramme: At 7 weeks of gestation (approximately 5 weeks after the first embryo transfer)
|
Presence of an intrauterine gestational sac on ultrasound after the first fresh or frozen embryo transfer from the index cycle, recorded per initiated index cycle and per transfer. Exploratory only; the study is not powered for this outcome. Reported descriptively. |
At 7 weeks of gestation (approximately 5 weeks after the first embryo transfer)
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Datoer for undersøgelser
Studer store datoer
Studiestart (Anslået)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Urogenitale sygdomme
- Genitale sygdomme
- Urogenitale sygdomme hos kvinder
- Kvinders urogenitale sygdomme og graviditetskomplikationer
- Kønssygdomme, kvindelige
- Infertilitet
- Infertilitet, kvinde
- Hormoner
- Hormoner, hormonsubstitutter og hormonantagonister
- Peptidhormoner
- Peptider
- Aminosyrer, peptider og proteiner
- Hypofysehormoner
- Gonadotropiner
- Hypofysehormoner, anterior
- Gonadotropiner, hypofyse
- Follikelstimulerende hormon
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- OPTIMAL-DOSE-OBS-2026-001
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .